PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50122C00031Advanced research and development and delivery — Crossject

Crossject holds $11.3M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Jun 21, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Crossject

Recipient

Jun 21, 2027

PoP end

$104.2M

Obligated

541714

NAICS

AN13

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Crossject — $90

Contract facts

NONE

Contract number75A50122C00031

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentCrossject

UEINLXZHCL3NLL3

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13

Related solicitation75A50121R00003

PoP end (current)Jun 21, 2027

PoP end (w/ options)Jun 21, 2030

Obligated$104.2M

ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGE… is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Crossject. Estimated value $104.2M ($104.2M obligated). Current period of performance ends Jun 21, 2027 (potential Jun 21, 2030). Last award drew 1 bidder. Related solicitation 75A50121R00003.

ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+

Recompete timing

Public

● Expiring in 288 days

Current PoP ends Jun 21, 2027 (288 days remaining). Agencies typically plan 12–18 months ahead — at 9.5 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Crossject — $11.3M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$11.3M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50122C00031?

75A50122C00031 (Advanced research and development and delivery) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $104.2M, currently held by Crossject. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50122C00031?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50122C00031 to Crossject.

Who is the incumbent on 75A50122C00031?

Crossject is the incumbent with $11.3M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Jun 21, 2027.

When does Crossject’s 75A50122C00031 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 21, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50122C00031 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Sep 16, 2025